Stocks and Investing Stocks and Investing
Tue, December 18, 2018
Mon, December 17, 2018
Fri, December 14, 2018

David Risinger Downgraded (AMRX) to Hold and Decreased Target to $18 on, Dec 14th, 2018


Published on 2024-10-26 11:16:57 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Morgan Stanley, Downgraded "Amneal Pharmaceuticals, Inc." (AMRX) to Hold and Decreased Target from $24 to $18 on, Dec 14th, 2018.

David has made no other calls on AMRX in the last 4 months.



There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Dewey Steadman of "Canaccord Genuity" Maintained at Hold with Increased Target to $21 on, Tuesday, August 14th, 2018


This is the rating of the analyst that currently disagrees with David


  • David Buck of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $28 on, Wednesday, August 22nd, 2018
Contributing Sources